CoChat

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

Open access
Giuliano, Mario, Giordano, Antonio, Jackson, Summer, De Giorgi, Ugo, Mego, Michal, Cohen, Evan N, Gao, Hui, Anfossi, Simone, Handy, Beverly C, Ueno, Naoto T, Alvarez, Ricardo H, De Placido, Sabino, Valero, Vicente, Hortobagyi, Gabriel N, Reuben, James M, Cristofanilli, Massimo · 2014 · Breast Cancer Research
Cited by 124

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination. Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood, pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at baseline and at the time of treatment failure, using Fisher’s exact test. Time to visceral progression and time to the development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between groups according to pretreatment CTC count by logrank test. Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline number of metastatic sites compared with <5 CTCs/7.5 ml (P = 0.0077). At the time of treatment failure, patients with ≥5 CTCs/7.5 ml more frequently developed new metastatic lesions and sites compared with those with <5 CTCs/7.5 ml (development of new lesions: P = 0.0002; development of new sites: P = 0.0031). Among patients with disease originally confined to nonvisceral sites, ≥5 CTCs/7.5 ml was associated with remarkably shorter time to visceral metastases (P = 0.0021) and overall survival (P = 0.0006) compared with <5 CTCs/7.5 ml. In patients with single-site metastatic disease, ≥5 CTCs/7.5 ml was associated with a significant reduction of the time to development of new metastatic sites (P = 0.0051) and new lesions (P = 0.0002) and with worse overall survival (P = 0.0101). Conclusion: Our results suggest that baseline CTC counts can be used as an early predictor of metastatic potential in breast cancer patients with limited metastatic dissemination.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13058-014-0440-8

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 124

Metadata

Authors
Giuliano, M., Giordano, A., Jackson, S., De Giorgi, U., Mego, M., Cohen, E. N., Gao, H., Anfossi, S., Handy, B. C., Ueno, N. T., Alvarez, R. H., De Placido, S., Valero, V., Hortobagyi, G. N., Reuben, J. M., & Cristofanilli, M.
Venue
Breast Cancer Research
Published
2014-09-16
Volume
16
Issue
5
Pages
440-440
ISSN
  • 1465-5411 (ISSN-L)
  • 1465-542X
OpenAlex
W2129833022
Cited by
124
References
1
FWCI
4.37
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. https://app.cochat.ai/papers/10.1186/s13058-014-0440-8
The paper
Giuliano, M., Giordano, A., Jackson, S., De Giorgi, U., Mego, M., Cohen, E. N., Gao, H., Anfossi, S., Handy, B. C., Ueno, N. T., Alvarez, R. H., De Placido, S., Valero, V., Hortobagyi, G. N., Reuben, J. M., & Cristofanilli, M. (2014). Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research. https://doi.org/10.1186/s13058-014-0440-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.